G-PN is a new vaccine which is a whole cell pneumococcal treatment that is inactivated by the presence of gamma irradiation. This biologic is said to have the capability to eliminate all of the 90 known structures of the pneumococcus bacteria - Streptococcus pneumonia.
Remote working is exploding as a result of mobile technologies. A growing segment of the workforce prefers it, and it saves huge spend on real estate and related costs. But lagging behind the rapid technology expansion is well thought through organizational strategy to absolutely ensure that remote workers are as productive and as engaged as their in-house counterparts.
The world’s first cognitive computer. This is a device that can rapidly analyse the collective research and recommendations of leading professionals, in order to advise healthcare professionals and improve patient outcomes. To find out more, we speak with Dr James Miser, Chief Medical Information Officer at Bumrungrad International Hospital, who describes the implementation process so far and how the technology is likely to transform healthcare.
Safeguarding of information that the pharmaceutical industry disseminates via social media is essential. Although pharmaceutical industry websites contain a wealth of useful information, there appears to be a general apprehension in their use to disseminate medically relevant information
Much growth in the sector is being driven by expansion into developing markets, thus increasing demand for people with international experience. Taking the supply chain as an example, although track-and-trace initiatives should simplify and facilitate logistics in the long-term, in the short term there may be increasing competition for those with specialist knowledge of developing markets.
A single error that occurs in a pharmaceutical lab adversely impacts the health of thousands of patients. This is exactly why calibration in a pharmaceutical facility is highly regulated for precision and repeatability
As Poland announces plans to create a British-style NHS, a recent paper has proposed that one priority should be to address the potential blurred boundaries between public bureaucracies, politicians and industry providers such as pharmaceutical companies.
Pharma and Cold Chain IQ explores the varying views and predictions on the potential outcomes which could occur from Brexit.
Traditionally the pharma industry has lent toward the view of adhering to a one-size fits all approach to the application of therapeutics. However, now eyes are set firmly on the notion of personalised medicine – therapeutics tailored to a patient’s specific biomarker information. The progression of next generation sequencing and genome technology is allowing for the first tangible personalised therapies to emerge.
Pharma IQ takes a look at some of the industry’s most prestigious movers and shakers causing ripples in the market over the last few months.